Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HLA-DRB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HLA-DRB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HLA-DRB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HLA-DRB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HLA-DRB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HLA-DRB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HLA-DRB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HLA-DRB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HLA-DRB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HLA-DRB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HLA-DRB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HLA-DRB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HLA-DRB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001583321 | Stomach | CSG | peptide transport | 26/1034 | 264/18723 | 3.14e-03 | 2.92e-02 | 26 |
GO:00024242 | Stomach | CSG | T cell mediated immune response to tumor cell | 4/1034 | 12/18723 | 3.20e-03 | 2.92e-02 | 4 |
GO:00027111 | Stomach | CSG | positive regulation of T cell mediated immunity | 9/1034 | 56/18723 | 3.36e-03 | 3.04e-02 | 9 |
GO:00508512 | Stomach | CSG | antigen receptor-mediated signaling pathway | 24/1034 | 240/18723 | 3.65e-03 | 3.26e-02 | 24 |
GO:000854421 | Stomach | CSG | epidermis development | 30/1034 | 324/18723 | 3.99e-03 | 3.47e-02 | 30 |
GO:00027631 | Stomach | CSG | positive regulation of myeloid leukocyte differentiation | 9/1034 | 58/18723 | 4.28e-03 | 3.68e-02 | 9 |
GO:00024602 | Stomach | CSG | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/1034 | 356/18723 | 4.71e-03 | 3.95e-02 | 32 |
GO:00023811 | Stomach | CSG | immunoglobulin production involved in immunoglobulin-mediated immune response | 10/1034 | 70/18723 | 4.91e-03 | 4.08e-02 | 10 |
GO:00456551 | Stomach | CSG | regulation of monocyte differentiation | 5/1034 | 21/18723 | 4.93e-03 | 4.08e-02 | 5 |
GO:00019141 | Stomach | CSG | regulation of T cell mediated cytotoxicity | 7/1034 | 39/18723 | 5.00e-03 | 4.10e-02 | 7 |
GO:00466512 | Stomach | CSG | lymphocyte proliferation | 27/1034 | 288/18723 | 5.17e-03 | 4.19e-02 | 27 |
GO:00025734 | Stomach | CSG | myeloid leukocyte differentiation | 21/1034 | 208/18723 | 5.63e-03 | 4.50e-02 | 21 |
GO:00022531 | Stomach | CSG | activation of immune response | 33/1034 | 375/18723 | 5.70e-03 | 4.54e-02 | 33 |
GO:003007321 | Stomach | CSG | insulin secretion | 20/1034 | 195/18723 | 5.72e-03 | 4.55e-02 | 20 |
GO:00329431 | Stomach | CSG | mononuclear cell proliferation | 27/1034 | 291/18723 | 5.93e-03 | 4.66e-02 | 27 |
GO:001603231 | Stomach | CAG | viral process | 37/552 | 415/18723 | 2.37e-09 | 4.06e-07 | 37 |
GO:001905831 | Stomach | CAG | viral life cycle | 31/552 | 317/18723 | 5.55e-09 | 7.99e-07 | 31 |
GO:004440331 | Stomach | CAG | biological process involved in symbiotic interaction | 28/552 | 290/18723 | 4.03e-08 | 4.39e-06 | 28 |
GO:00480023 | Stomach | CAG | antigen processing and presentation of peptide antigen | 12/552 | 62/18723 | 2.16e-07 | 1.82e-05 | 12 |
GO:001988331 | Stomach | CAG | antigen processing and presentation of endogenous antigen | 8/552 | 26/18723 | 5.30e-07 | 3.95e-05 | 8 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0414518 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0532312 | Breast | Precancer | Rheumatoid arthritis | 19/684 | 93/8465 | 1.30e-04 | 1.14e-03 | 8.73e-04 | 19 |
hsa0541618 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0414519 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0532313 | Breast | Precancer | Rheumatoid arthritis | 19/684 | 93/8465 | 1.30e-04 | 1.14e-03 | 8.73e-04 | 19 |
hsa0541619 | Breast | Precancer | Viral myocarditis | 14/684 | 60/8465 | 2.32e-04 | 1.98e-03 | 1.52e-03 | 14 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0541623 | Breast | IDC | Viral myocarditis | 18/867 | 60/8465 | 1.85e-05 | 2.01e-04 | 1.50e-04 | 18 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0532321 | Breast | IDC | Rheumatoid arthritis | 21/867 | 93/8465 | 3.69e-04 | 3.15e-03 | 2.36e-03 | 21 |
hsa0494014 | Breast | IDC | Type I diabetes mellitus | 12/867 | 43/8465 | 9.40e-04 | 7.28e-03 | 5.44e-03 | 12 |
hsa0533012 | Breast | IDC | Allograft rejection | 11/867 | 38/8465 | 1.09e-03 | 8.26e-03 | 6.18e-03 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-DRB1 | SNV | Missense_Mutation | rs754953589 | c.202C>T | p.Arg68Cys | p.R68C | P04229,Q9GIY3,P01911,Q29974 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-DRB1 | SNV | Missense_Mutation | rs761045049 | c.100C>T | p.Pro34Ser | p.P34S | P04229,Q9GIY3,P01911,Q29974 | protein_coding | tolerated(0.24) | benign(0) | TCGA-G5-6641-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
HLA-DRB1 | SNV | Missense_Mutation | novel | c.330C>A | p.His110Gln | p.H110Q | P04229,Q9GIY3,P01911,Q29974 | protein_coding | deleterious(0.03) | possibly_damaging(0.735) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
HLA-DRB1 | SNV | Missense_Mutation | novel | c.380A>T | p.Lys127Met | p.K127M | P04229,Q9GIY3,P01911,Q29974 | protein_coding | tolerated(0.11) | benign(0.376) | TCGA-DF-A2KS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HLA-DRB1 | SNV | Missense_Mutation | novel | c.154N>T | p.Arg52Trp | p.R52W | P04229,Q9GIY3,P01911,Q29974 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-PG-A6IB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HLA-DRB1 | SNV | Missense_Mutation | novel | c.460G>C | p.Gly154Arg | p.G154R | P04229,Q9GIY3,P01911,Q29974 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-34-2609-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | PD |
HLA-DRB1 | SNV | Missense_Mutation | | c.469G>A | p.Glu157Lys | p.E157K | P04229,Q9GIY3,P01911,Q29974 | protein_coding | tolerated(0.41) | probably_damaging(0.996) | TCGA-37-3789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HLA-DRB1 | SNV | Missense_Mutation | rs17885257 | c.235N>T | p.Val79Leu | p.V79L | P04229,Q9GIY3,P01911,Q29974 | protein_coding | tolerated(0.2) | probably_damaging(0.974) | TCGA-63-6202-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
HLA-DRB1 | insertion | Frame_Shift_Ins | novel | c.331_332insCA | p.Asn111ThrfsTer19 | p.N111Tfs*19 | P04229,Q9GIY3,P01911,Q29974 | protein_coding | | | TCGA-CN-A642-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | flupirtine | FLUPIRTINE | 26959717 |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | methimazole | METHIMAZOLE | |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | aspirin | ASPIRIN | 15784113,19392989 |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | fluvastatin | FLUVASTATIN | 27839692 |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | infliximab | INFLIXIMAB | |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | efavirenz | EFAVIRENZ | 18301070 |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | adalimumab | ADALIMUMAB | |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | propylthiouracil | PROPYLTHIOURACIL | |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Influenza vaccines | | 11756990 |
3123 | HLA-DRB1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Tumor necrosis factor alpha (TNF-alpha) inhibitors | | |